Maze Therapeutics CMO exercises options, sells shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 14,853 shares of common stock at an exercise price of $10.42 per share, then sold all 14,853 shares in open-market transactions at weighted average prices of $25.57 and $26.36 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan, and he reported no directly held common shares afterward while retaining 207,554 stock options following the option exercise.
Insider Trade Summary 10b5-1
Exercise and Sale: 14,853 shares ($226K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Bernstein Harold
Role
President, R&D & CMO
Sold
14,853 shs ($381K)
Approx. gross sale proceeds
$381K
Approx. exercise cost
$155K
Approx. pre-tax spread
$226K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 14,853 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,853 | $10.42 | $155K |
| Sale | Common Stock | 13,253 | $25.5746 | $339K |
| Sale | Common Stock | 1,600 | $26.3576 | $42K |
Holdings After Transaction:
Stock Option (Right to Buy) — 207,554 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive.
- F4. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Shares sold: 14,853 shares
First sale size and price: 13,253 shares at $25.5746/share
Second sale size and price: 1,600 shares at $26.3576/share
+3 more
6 metrics
Shares sold
14,853 shares
Total Maze Therapeutics common stock sold on open market
First sale size and price
13,253 shares at $25.5746/share
Weighted average sale price; trades between $25.16 and $26.10
Second sale size and price
1,600 shares at $26.3576/share
Weighted average sale price; trades between $26.16 and $26.53
Options exercised
14,853 shares at $10.42/share
Stock option exercise price for Maze Therapeutics common stock
Options remaining
207,554 stock options
Stock options outstanding after partial exercise
Option expiration
2032-10-26
Expiration date for the reported stock option award
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan financial
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MAZE executive Harold Bernstein report?
Harold Bernstein reported exercising stock options for 14,853 Maze Therapeutics shares and immediately selling all 14,853 shares in open-market transactions. The activity reflects an exercise-and-sell pattern rather than a new open-market purchase, and was executed under a Rule 10b5-1 trading plan.
What was the stock option exercise price in Harold Bernstein’s MAZE Form 4?
Bernstein exercised stock options covering 14,853 Maze Therapeutics shares at an exercise price of $10.42 per share. The options were part of an award that vested over time, with vesting beginning on October 3, 2023, subject to his continued service with the company.
Does Harold Bernstein still hold Maze Therapeutics stock options after these transactions?
Yes. After exercising 14,853 options, Bernstein reported 207,554 stock options remaining. These options relate to Maze Therapeutics common stock and have an exercise price of $10.42 per share, with an expiration date in 2032, based on the derivative transaction entry.
AI-generated analysis. How Rhea-AI works. Not financial advice.
